BRAF and colorectal carcinoma: When we tested the MEK signature against the eight KRAS wild-type and one BRAF mutant PDX models treated with TAK-733, the prediction accuracy was only 44%, suggesting that the MEK signature is only predictive for KRAS mutant CRC (Table 4).